{"slug":"mots-c","seoKey":"motsc","displayName":"MOTS-c","codes":[],"synonyms":["mitochondrial open reading frame of the 12S rRNA type-c","mitochondria-derived peptide MOTS-c","mitochondrial-derived peptide (MDP) MOTS-c","H-MRWQEMGYIFYPRKLR-OH"],"legalClass":"research_chemical","identifiers":{"cas":"1627580-64-6","pubchemCid":146675088,"unii":"A5CV6JFB78","inchikey":"WYTHCOXVWRKRAH-LOKRTKBUSA-N","wikidataQid":"Q56377357","formula":"C101H152N28O22S2","molecularWeight":2174.6,"sequence":"MRWQEMGYIFYPRKLR"},"approvals":[{"market":"US","status":"not_approved","note":"No approval as a medicine and not on the 503A bulks list for compounding; the agency proposed against inclusion in 2026 and no final decision existed on 2026-09-06.","source":"https://www.fda.gov/media/193342/download"},{"market":"EU","status":"not_approved","note":"No centralised marketing authorisation and no assessment report. No entry found on 2026-09-06.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=MOTS-c"},{"market":"DE","status":"not_approved","note":"No national or EU marketing authorisation; no finished medicinal product is marketable. No entry found on 2026-09-06.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=MOTS-c"},{"market":"UK","status":"not_approved","note":"No marketing authorisation; treated as an unlicensed medicine. No entry found on 2026-09-06.","source":"https://products.mhra.gov.uk/search/?search=MOTS-c"},{"market":"AU","status":"not_approved","note":"No entry in the Australian Register of Therapeutic Goods and not named in the Poisons Standard; handled as an unapproved therapeutic good. No entry found on 2026-09-06.","source":"https://www.tga.gov.au/news/media-releases/tga-strengthens-compliance-focus-unapproved-peptide-products-part-evolving-risk-response"},{"market":"CA","status":"not_approved","note":"No marketing authorisation and no drug identification number. Database query returned no result on 2026-09-06.","source":"https://health-products.canada.ca/api/drug/activeingredient/"},{"market":"CH","status":"not_approved","note":"No marketing authorisation; distribution of unapproved medicines within Switzerland is unlawful. No entry found on 2026-09-06.","source":"https://www.bazg.admin.ch/de/newnsb/aTkecQempbtqCwVzr61G_"}],"devStage":"phase1","strongestEvidence":"observational","wada":{"status":"prohibited","section":"S4.4.1","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[{"nct":"NCT03998514","name":"CB4211 (MOTS-c analogue) in healthy participants and in non-alcoholic fatty liver disease","phase":"Phase 1a/1b","n":88,"status":"COMPLETED"},{"nct":"NCT04013568","name":"Exercise post-diagnosis of breast cancer (MOTS-c measured as a blood marker)","phase":"N/A","n":62,"status":"COMPLETED"},{"nct":"NCT07678073","name":"Anaesthesia technique and ferroptosis, humanin and MOTS-c levels in renal transplantation (MOTS-c measured as a marker)","phase":"N/A","n":68,"status":"RECRUITING"},{"nct":"NCT04027712","name":"Platelet reactivity, beta-amyloid, MOTS-c and mortality in type 2 diabetes with coronary artery disease (MOTS-c measured as a marker)","phase":"Observational","n":120,"status":"UNKNOWN"}],"sameAs":["https://www.wikidata.org/wiki/Q56377357","https://pubchem.ncbi.nlm.nih.gov/compound/146675088"],"lastVerified":"2026-09-06","version":"1.0","published":true,"locale":"en","title":"MOTS-c: what the studies show, status and safety","summary":"MOTS-c is a short peptide of 16 amino acid building blocks, and the instructions for making it sit inside the DNA of our cells' own power plants, the mitochondria. It was first described in 2015. Almost everything known about giving it as a drug comes from mice. No country has approved it as a medicine, and no verified trial has ever given the peptide itself to people. It is banned in sport at all times.","updated":"2026-09-06","url":"https://mypep.app/peptides/mots-c"}